ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2087

Defective Circadian Control in Mesenchymal Cells Reduces Adult Bone Mass

Julia F. Charles1 and Joerg Ermann2, 1Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Bone, Mouse model, osteoblasts and osteoclasts

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Biology and Pathology of Bone and Joint: Bone Remodeling

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Genetic disruption of the circadian molecular clock in mice is a powerful tool to dissect the role of circadian rhythms in health and disease. Several bone turnover markers show circadian variation in humans suggesting a function for the circadian molecular clock in bone physiology. In contrast to previous reports, we found that at 8 weeks of age (prior to the onset of heterotopic ossification) mice with germline deletion of the core circadian regulator Bmal1 (Brain and muscle Arntl-like 1, Bmal1-/-) have reduced trabecular and cortical bone compared with wildtype mice. Here, we ask whether the development of this phenotype can be mapped to disruption of the molecular clock in mesenchymal cells, osteoclasts, or both.

Methods: We generated mice with conditional deletion of Bmal1 in mesenchymal cells of the limbs (Prx1-cre) or osteoclasts (Ctk-cre). We analyzed the bone phenotype of 8 week-old male mice comparing Bmal1fl/fl.Prx1-cre mice with Bmal1fl/fl littermate controls, and Bmal1fl/fl.Ctk-cre mice with Bmal1fl/+.Ctk-cre littermate controls, respectively. Femurs were examined by micro-computed tomography and histology, and in vitroosteoclast and osteoblast differentiation assays were performed. 

Results: Deletion of Bmal1 in osteoclasts had no effect on in vitro osteoclast differentiation or resorptive function. Consistent with this, no differences in trabecular or cortical bone parameters were seen in Bmal1fl/fl.Ctk-cre compared with Bmal1fl/+.Ctk-cre controls. In contrast, we found a significant reduction of trabecular bone in Bmal1fl/fl.Prx1-cre mice compared with controls (BV/TV 14.9% vs. 20.5% p=0.002; n=14) with corresponding significant changes in trabecular number, thickness, spacing and connectivity. Cortical parameters were also affected (C.Th.  0.15mm vs 0.17mm, p=0.008; n=14). In vitro assays failed to reveal an effect of mesenchymal Bmal1 deletion on osteoclast formation or function. Differentiation of osteoblasts from Bmal1fl/fl.Prx1-cre bone marrow stromal cells was also not significantly different from controls. 

Conclusion: These results demonstrate that bone mass in mice is controlled by the cell-intrinsic circadian molecular clock in mesenchymal cells, whereas a functioning clock in osteoclasts appears dispensable for maintaining bone homeostasis.


Disclosure: J. F. Charles, None; J. Ermann, None.

To cite this abstract in AMA style:

Charles JF, Ermann J. Defective Circadian Control in Mesenchymal Cells Reduces Adult Bone Mass [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/defective-circadian-control-in-mesenchymal-cells-reduces-adult-bone-mass/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/defective-circadian-control-in-mesenchymal-cells-reduces-adult-bone-mass/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology